342 related articles for article (PubMed ID: 35063726)
1. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
[TBL] [Abstract][Full Text] [Related]
2. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
3. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
[TBL] [Abstract][Full Text] [Related]
4. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
Ambrosius W; Michalak S; Kozubski W; Kalinowska A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
[TBL] [Abstract][Full Text] [Related]
7. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
8. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
9. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
[TBL] [Abstract][Full Text] [Related]
11. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases.
Guzmán J; Vera F; Soler B; Uribe-San-Martin R; García L; Del-Canto A; Schlatter A; Salazar M; Molt F; Ramirez K; Marín J; Pelayo C; Cruz JP; Bravo-Grau S; Cárcamo C; Ciampi E
Mult Scler Relat Disord; 2023 Jan; 69():104442. PubMed ID: 36521387
[TBL] [Abstract][Full Text] [Related]
12. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
[TBL] [Abstract][Full Text] [Related]
13. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.
Rigal J; Ciron J; Lépine Z; Biotti D
Mult Scler Relat Disord; 2020 Jun; 41():102019. PubMed ID: 32151983
[TBL] [Abstract][Full Text] [Related]
14. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
15. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
[TBL] [Abstract][Full Text] [Related]
16. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder.
Molazadeh N; Filippatou AG; Vasileiou ES; Levy M; Sotirchos ES
J Neuroimmunol; 2021 Nov; 360():577702. PubMed ID: 34547512
[TBL] [Abstract][Full Text] [Related]
17. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Hacohen Y; Wong YY; Lechner C; Jurynczyk M; Wright S; Konuskan B; Kalser J; Poulat AL; Maurey H; Ganelin-Cohen E; Wassmer E; Hemingway C; Forsyth R; Hennes EM; Leite MI; Ciccarelli O; Anlar B; Hintzen R; Marignier R; Palace J; Baumann M; Rostásy K; Neuteboom R; Deiva K; Lim M
JAMA Neurol; 2018 Apr; 75(4):478-487. PubMed ID: 29305608
[TBL] [Abstract][Full Text] [Related]
18. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
Kwon YN; Kim B; Ahn S; Seo J; Kim SB; Yoon SS; Sung JJ; Choi YS; Kim SM
J Neuroimmunol; 2020 Nov; 348():577361. PubMed ID: 32919144
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
Tajfirouz DA; Bhatti MT; Chen JJ
Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
